- Home
- GSIW vs AYTU Comparison
GSIW vs AYTU Comparison
Compare GSIW & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- AYTU
- Stock Information
- Founded
- GSIW 2016
- AYTU N/A
- Country
- GSIW Hong Kong
- AYTU United States
- Employees
- GSIW N/A
- AYTU N/A
- Industry
- GSIW
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- AYTU Health Care
- Exchange
- GSIW Nasdaq
- AYTU Nasdaq
- Market Cap
- GSIW 8.3M
- AYTU 8.3M
- IPO Year
- GSIW 2023
- AYTU N/A
- Fundamental
- Price
- GSIW $0.64
- AYTU $2.59
- Analyst Decision
- GSIW
- AYTU
- Analyst Count
- GSIW 0
- AYTU 0
- Target Price
- GSIW N/A
- AYTU N/A
- AVG Volume (30 Days)
- GSIW 1.9M
- AYTU 3.4M
- Earning Date
- GSIW 12-31-2024
- AYTU 05-14-2025
- Dividend Yield
- GSIW N/A
- AYTU N/A
- EPS Growth
- GSIW N/A
- AYTU N/A
- EPS
- GSIW N/A
- AYTU N/A
- Revenue
- GSIW $1,313,795.00
- AYTU $77,232,000.00
- Revenue This Year
- GSIW N/A
- AYTU N/A
- Revenue Next Year
- GSIW N/A
- AYTU $8.14
- P/E Ratio
- GSIW N/A
- AYTU N/A
- Revenue Growth
- GSIW N/A
- AYTU N/A
- 52 Week Low
- GSIW $0.35
- AYTU $0.95
- 52 Week High
- GSIW $12.30
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- GSIW 63.72
- AYTU 82.21
- Support Level
- GSIW $0.43
- AYTU $1.20
- Resistance Level
- GSIW $1.03
- AYTU $1.31
- Average True Range (ATR)
- GSIW 0.09
- AYTU 0.13
- MACD
- GSIW 0.03
- AYTU 0.05
- Stochastic Oscillator
- GSIW 41.22
- AYTU 74.52
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.